ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 2781

Assessing RA Disease Activity with Promis Measures Using Smartphone Technology

Huifeng Yun1, Shuo Yang2, W. Benjamin Nowell3, Cooper Filby1, Lang Chen1 and Jeffrey R. Curtis4, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Disease Activity, Outcome measures, PROMIS, rheumatoid arthritis (RA) and technology

Session Information

Date: Tuesday, November 7, 2017

Title: Patient Outcomes, Preferences, and Attitudes II

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and reduce participant burden. The bridge between PROMIS and traditional patient-reported PROs (e.g. RAPID3) is not clear, and it might be possible that some instruments in PROMIS might proxy for measuring more lengthy PROs.

Methods:  Four PROMIS CAT instruments: Pain Interference, Physical Function, Sleep Disturbance, Fatigue, and a visual analog scale (Pain Intensity);and the Routine Assessment of Patient Index Data 3 (RAPID3) were administered to participants in the PCORI-funded ArthritisPower patient registry via a mobile application (App) on their smartphone or computer. The RAPID3 was evaluated in terms of multiple correlations (Pearson) with PROMIS and total variance explained using mixed models. Both the RAPID3 score and category was predicted using the selected 4 PROMIS instruments and pain intensity to form a new predicted score (“CAT-PROMIS RAPID3”). Kappa statistics and Bland-Altman 95% limits of agreement (LOA) were used to measure agreement between the measured RAPID3 and the predicted CAT-PROMIS RAPID3.

Results:  At the time of analysis, 2,376 patients had answered all five PROMIS instruments and the RAPID3 and contributed 3906 observations. Mean +-SD age was 51.6 +/- 10.5 years; 90% were women. Most (81%) had high RAPID3 scores. The mean assessment time for each of the PROMIS instruments ranged from a low of 16 seconds (sleep disturbance) to a high of 105 seconds (RAPID3).As single pairwise comparisons, the 4 PROMIS CATs examined were only modestly correlated (r ~ 0.2-0.4) to one other and the RAPID3. However, in aggregate, the PROMIS instruments explained a very high fraction of total variance (R2=80%) of the RAPID3. The measured RAPID3 was very highly correlated with the CAT-PROMIS predicted RAPID3 (r=0.97). Overall agreement (table) between categories of the RAPID3 vs. CAT-PROMIS RAPID3 also was very high (kappa = 0.81). Bland-Altman 95% limits of agreement shows minimal residual differences and no systematic biases.

Conclusion: There was excellent agreement between the measured RAPID3 and a predicted RAPID3 score estimated using several PROMIS instruments. Few if any questions in the RAPID3 may need to be measured if PROMIS scores are available. 

 

Table. Cross Classification of Patient-reported RAPID3 versus predicted PROMIS-CAT RAPID3

 

PREDICTED CAT-PROMIS RAPID3

RAPID3

Near remission

Low

Moderate

High

Near remission

   34

15

1

0

Low

2

66

45         

0

Moderate

1

6

       423

133

High

0

0

21

3,159

 


Disclosure: H. Yun, BMS, 2; S. Yang, None; W. B. Nowell, Global Healthy Living Foundation, 3; C. Filby, None; L. Chen, None; J. R. Curtis, UCB Pharma, Janssen-Cilag, Amgen, Roche, Myriad Genetics, Lilly, Novartis, BMS, Pfizer, 2,UCB Pharma, Janssen-Cilag, Amgen, Roche, Myriad Genetics, Lilly, Novartis, BMS, Pfizer, 5.

To cite this abstract in AMA style:

Yun H, Yang S, Nowell WB, Filby C, Chen L, Curtis JR. Assessing RA Disease Activity with Promis Measures Using Smartphone Technology [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/assessing-ra-disease-activity-with-promis-measures-using-smartphone-technology/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-ra-disease-activity-with-promis-measures-using-smartphone-technology/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology